BioRestorative Therapies, Inc. (BRTX)

NASDAQ: BRTX · IEX Real-Time Price · USD
1.740
-0.030 (-1.69%)
Jul 16, 2024, 11:00 AM EDT - Market open
-1.69%
Market Cap 12.34M
Revenue (ttm) 149,500
Net Income (ttm) -6.96M
Shares Out 6.77M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,819
Open 1.800
Previous Close 1.770
Day's Range 1.740 - 1.822
52-Week Range 1.030 - 3.670
Beta 62.85
Analysts Strong Buy
Price Target 15.00 (+762.07%)
Earnings Date Aug 9, 2024

About BRTX

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 11
Stock Exchange NASDAQ
Ticker Symbol BRTX
Full Company Profile

Financial Performance

In 2023, BRTX's revenue was $145,800, an increase of 21.70% compared to the previous year's $119,800. Losses were -$10.42 million, -21.21% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BRTX stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(762.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –

19 days ago - GlobeNewsWire

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRest...

4 weeks ago - GlobeNewsWire

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders –

4 weeks ago - GlobeNewsWire

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today...

6 weeks ago - GlobeNewsWire

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.  (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therap...

7 weeks ago - GlobeNewsWire

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

MELVILLE, NY / ACCESSWIRE / May 15, 2024 / As advancements in technology make it easier to enhance natural beauty, the global aesthetics market, which was worth $75.46 billion in 2023, is expected to ...

2 months ago - Accesswire

BioRestorative Therapies Provides First Quarter 2024 Business Update

MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapi...

2 months ago - GlobeNewsWire

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

— New therapeutic candidate developed using Company's patented ThermoStem ® platform —

2 months ago - GlobeNewsWire

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity -

2 months ago - GlobeNewsWire

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform —

2 months ago - GlobeNewsWire

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.

3 months ago - GlobeNewsWire

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity —

3 months ago - GlobeNewsWire

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) ...

3 months ago - GlobeNewsWire

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based thera...

3 months ago - GlobeNewsWire

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, t...

4 months ago - GlobeNewsWire

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease ...

5 months ago - Accesswire

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, toda...

5 months ago - GlobeNewsWire

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOB...

5 months ago - GlobeNewsWire

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST...

5 months ago - GlobeNewsWire

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

--Notice of allowance will be the fourth U.S. patent granted under Company's ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023 (...

7 months ago - GlobeNewsWire

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announ...

10 months ago - GlobeNewsWire

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chr...

10 months ago - Accesswire

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

-- BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to S upply B iologics for C osmetic A pplications in Strategic Agreement

11 months ago - GlobeNewsWire

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

--Site activation allows for patients in the S tate of New York to participate in the BRTX-100 t rial —

11 months ago - GlobeNewsWire

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

MELVILLE, NY / ACCESSWIRE / August 30, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the populati...

11 months ago - Accesswire